Zonisamid EQL Pharma launched in Denmark

The drug Zonisamid EQL Pharma has today been launched on the Danish market.

Zonisamide EQL Pharma is an antiepileptic, used for the treatment of epilepsy. The original is called Zonegran (Eisai Limited).
The total turnover of Zonisamid in Denmark is approximately SEK 10 million annually. Currently the original and 3 competitors are on the market.

For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com 

EQL Pharma AB (publ) in brief

EQL Pharma is specialized in developing and selling generic drugs, ie drugs that are medically equivalent to the original medicines. The company currently markets 8 niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently focused entirely on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs 7 (8) people and is listed on AktieTorget. EQL Pharma conducts extensive development in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and China.